



*Received*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **RECEIVED**

AUG 20 2001

In re Application of

POMPEJUS et al.

Serial No. 09/582,779

Filed: July 3, 2000

For: OROTIDINE-5'-PHOSPHATE DECARBOXYLASE-GENE, GENE CONSTRUCT  
CONTAINING SAID GENE AND THE UTILIZATION THEREOF

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope  
addressed to Commissioner of Patents and Trademarks, Washington,  
D.C. 20231, on:  
March 23, 2001

Date of Deposit

Monica K. Sims

Person Making Deposit

*Monica Sims*

Signature

March 23, 2001

Date of Signature

**REQUEST FOR CORRECTED FILING RECEIPT**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

Please forward a corrected filing receipt as follows:

Correct the Continuing Application data:

**It should read "This application is a 371 of PCT/EP98/08382, 12/18/98" not**

--This application is a 371 of PCT/EP98/08382, 1/15/98.--

The error is the fault of the Patent Office, no fee is required.

Respectfully submitted,

KEIL & WEINKAUF

Herbert B. Keil  
Reg. No. 18,967

1101 Connecticut Avenue, N.W.  
Washington, D.C. 20036  
(202) 659-0100  
HBK/mks



Page 1 of 2  
**RECEIVED**

AUG 20 2001

UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/582,779	07/03/2000	1632	840	48715	1	15	2

**CORRECTED FILING RECEIPT**

KEIL & WEINKAUF  
1101 CONNECTICUT AVENUE NW  
WASHINGTON, DC 20036



\*OC00000005874766\*

Date Mailed: 03/19/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

MARKUS POMPEJUS, WALDSEE, GERMANY;  
JOSE LUIS REVUELTRA DOVAL, SALAMANCA, SPAIN;  
MARIA ANGELES SANTOS GARCIA, SALAMANCA, SPAIN;

**Continuing Data as Claimed by Applicant**

THIS APPLICATION IS A 371 OF PCT/EP98/08382 01/15/1998

12118198

**Foreign Applications**

GERMANY 19801120.2 01/15/1998

If Required, Foreign Filing License Granted 08/17/2000

**Title**

OROTIDINE-5'-PHOSPHATE DECARBOXYLASE-GENE, GENE CONSTRUCT  
CONTAINING SAID GENE AND THE UTILIZATION THEREOF

**Preliminary Class**

435

Data entry by : SMALLWOOD, EAON

Team : 1600

Date: 03/19/2001





**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**RECEIVED**

AUG 20 2001

TECH CENTER 1600/2900

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)



Bib Data Sheet

**FILE COPY**

CONFIRMATION NO. 2744

SERIAL NUMBER 09/582,779	FILING DATE 07/03/2000 RULE	CLASS 435	GROUP ART UNIT 1636	ATTORNEY DOCKET NO. 48715
-----------------------------	-----------------------------------	--------------	------------------------	---------------------------------

**APPLICANTS**

MARKUS POMPEJUS, WALDSEE, GERMANY;  
 JOSE LUIS REVUELTRA DOVAL, SALAMANCA, SPAIN;  
 MARIA ANGELES SANTOS GARCIA, SALAMANCO, SPAIN;

**\*\* CONTINUING DATA \*\*\*\*\***

12/18/98  
 THIS APPLICATION IS A 371 OF PCT/EP98/08382 01/15/1998

**\*\* FOREIGN APPLICATIONS \*\*\*\*\***

GERMANY 19801120.2 01/15/1998

**IF REQUIRED, FOREIGN FILING LICENSE GRANTED**  
**\*\* 08/17/2000**

Foreign Priority claimed	<input type="checkbox"/> yes <input type="checkbox"/> no
35 USC 119 (a-d) conditions met	<input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance
Verified and Acknowledged	Examiner's Signature Initials
ADDRESS	KEIL & WEINKAUF 1101 CONNECTICUT AVENUE NW WASHINGTON , DC 20036
TITLE	OROTIDINE-5'-PHOSPHATE DECARBOXYLASE-GENE, GENE CONSTRUCT CONTAINING SAID GENE AND THE UTILIZATION THEREOF

FILING FEE RECEIVED 840	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other <input type="checkbox"/> Credit
----------------------------	---	---